

Cat. No. MHC-HE450B


Description	
Source	Recombinant Biotinylated Human HLA-A*02:01&B2M&NPM1-CLAV (CLAVEEVSL) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and CLAVEEVSL peptide.
Accession	A0A140T913(HLA-A*02:01)&P61769(B2M)&CLAVEEVSL
Molecular Weight	The protein has a predicted MW of 35.6 kDa (HLA-A*02:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

Formulation and Storage	
Formulation	Supplied as 0.22 µm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background	
The nucleophosmin (NPM1) mutant protein, a leukemia-associated antigen characterized by its leukemia-restricted expression and immunogenic potential, has emerged as a promising therapeutic target for acute myeloid leukemia (AML) immunotherapy. Among its immunogenic epitopes, the CLAVEEVSL peptide derived from the full C-terminal region of the NPM1-mutated isoform demonstrates potent immunogenicity, making it a prime candidate for T cell-based immunotherapies.	

Assay Data

Bis-Tris PAGE



SEC-HPLC

